Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2023 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results

- Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement - -...
March 21, 2023 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery

CHARLESTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
March 07, 2023 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences to Present at Barclays Global Healthcare Conference

CHARLESTOWN, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
February 08, 2023 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences to Present at SVB Securities Global Biopharma Conference

CHARLESTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
January 26, 2023 08:00 ET | Source: Solid Biosciences Inc.

Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA’s Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy

- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy...
January 11, 2023 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

Research collaboration to target severe form of genetic dilated cardiomyopathyCollaboration strengthens Solid Biosciences’ scientific capabilities and commercial potential in cardiac...
January 10, 2023 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences Outlines Strategy for Leadership in Precision Genetic Medicines with Focus on Neuromuscular and Cardiac Diseases

– Investigational New Drug (IND) application for SGT-003, next-generation gene therapy for Duchenne muscular dystrophy utilizing novel capsid AAV-SLB101, expected in 2H-2023 – – Candidate selection...
January 09, 2023 16:26 ET | Source: Solid Biosciences Inc.

Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer

CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
January 09, 2023 08:01 ET | Source: Solid Biosciences Inc.

Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer

CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
January 09, 2023 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...